

# Nigel Stallard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1331929/publications.pdf>

Version: 2024-02-01

191  
papers

6,120  
citations

76196

40  
h-index

102304

66  
g-index

201  
all docs

201  
docs citations

201  
times ranked

7112  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. <i>New England Journal of Medicine</i> , 2018, 379, 711-721.	13.9	495
2	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 546.	3.8	229
3	Optimal Adaptive Designs for Binary Response Trials. <i>Biometrics</i> , 2001, 57, 909-913.	0.8	207
4	The changing face of cardiovascular disease 2000â€“2012: An analysis of the world health organisation global health estimates data. <i>International Journal of Cardiology</i> , 2016, 224, 256-264.	0.8	197
5	Sequential designs for phase III clinical trials incorporating treatment selection. <i>Statistics in Medicine</i> , 2003, 22, 689-703.	0.8	171
6	Effectiveness of a Web-Based Cognitive-Behavioral Tool to Improve Mental Well-Being in the General Population: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2012, 15, e2.	2.1	142
7	HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial. <i>PLoS Medicine</i> , 2019, 16, e1002719.	3.9	131
8	Socioeconomic risk, parenting during the preschool years and child health age 6 years. <i>European Journal of Public Health</i> , 2007, 17, 508-513.	0.1	119
9	Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 99-119.	0.4	93
10	A groupâ€“sequential design for clinical trials with treatment selection. <i>Statistics in Medicine</i> , 2008, 27, 6209-6227.	0.8	90
11	DELTA <sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2018, 363, k3750.	2.4	90
12	A confirmatory seamless phase II/III clinical trial design incorporating shortâ€“term endpoint information. <i>Statistics in Medicine</i> , 2010, 29, 959-971.	0.8	84
13	Optimal sample sizes for phase II clinical trials and pilot studies. <i>Statistics in Medicine</i> , 2012, 31, 1031-1042.	0.8	84
14	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 214-225.	4.9	81
15	A conditional error function approach for subgroup selection in adaptive clinical trials. <i>Statistics in Medicine</i> , 2012, 31, 4309-4320.	0.8	80
16	Improving the Efficiency of Advanced Life Support Training. <i>Annals of Internal Medicine</i> , 2012, 157, 19.	2.0	79
17	An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several. <i>Journal of Biopharmaceutical Statistics</i> , 2005, 15, 641-658.	0.4	77
18	Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory. <i>Biometrics</i> , 1998, 54, 279.	0.8	73

#	ARTICLE	IF	CITATIONS
19	A newly devised scoring system for prediction of mortality in patients with colorectal cancer: a prospective study. <i>Lancet Oncology</i> , The, 2007, 8, 317-322.	5.1	69
20	Reduction in the rate of methicillin-resistant <i>Staphylococcus aureus</i> acquisition in surgical wards by rapid screening for colonization: a prospective, cross-over study. <i>Clinical Microbiology and Infection</i> , 2010, 16, 333-339.	2.8	68
21	Recommendations for the design of small population clinical trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 195.	1.2	68
22	Bayesian Graphical Models for Genomewide Association Studies. <i>American Journal of Human Genetics</i> , 2006, 79, 100-112.	2.6	63
23	Parenting and health in mid-childhood: a longitudinal study. <i>European Journal of Public Health</i> , 2008, 18, 300-305.	0.1	63
24	Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes. <i>Biometrics</i> , 1999, 55, 971-977.	0.8	59
25	Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. <i>Statistics in Medicine</i> , 2011, 30, 1528-1540.	0.8	57
26	The System-Wide Effect of Real-Time Audiovisual Feedback and Postevent Debriefing for In-Hospital Cardiac Arrest. <i>Critical Care Medicine</i> , 2015, 43, 2321-2331.	0.4	56
27	Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 168-187.	0.4	55
28	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	1.3	53
29	Subacromial balloon spacer for irreparable rotator cuff tears of the shoulder (START:REACTS): a group-sequential, double-blind, multicentre randomised controlled trial. <i>Lancet</i> , The, 2022, 399, 1954-1963.	6.3	53
30	Seamless phase II/III designs. <i>Statistical Methods in Medical Research</i> , 2011, 20, 623-634.	0.7	52
31	A Comparison of Methods for Adaptive Treatment Selection. <i>Biometrical Journal</i> , 2008, 50, 767-781.	0.6	51
32	A systematic literature review of the risk factors associated with children entering public care. <i>Child: Care, Health and Development</i> , 2013, 39, 628-642.	0.8	50
33	DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. <i>Trials</i> , 2018, 19, 606.	0.7	50
34	Point estimates and confidence regions for sequential trials involving selection. <i>Journal of Statistical Planning and Inference</i> , 2005, 135, 402-419.	0.4	49
35	Should randomised controlled trials be the "gold standard" for research on preventive interventions for children?. <i>Journal of Children's Services</i> , 2011, 6, 228-235.	0.5	49
36	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	2.4	49

#	ARTICLE	IF	CITATIONS
37	A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 81-88.	1.4	46
38	Pre-hospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): Trial protocol. <i>Resuscitation</i> , 2016, 108, 75-81.	1.3	43
39	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	0.8	43
40	Association of maternal vitamin B12 and folate levels in early pregnancy with gestational diabetes: a prospective UK cohort study (PRiDE study). <i>Diabetologia</i> , 2021, 64, 2170-2182.	2.9	42
41	Emergency nurse practitioners and doctors consulting with patients in an emergency department: a comparison of communication skills and satisfaction. <i>Emergency Medicine Journal</i> , 2009, 26, 400-404.	0.4	41
42	Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. <i>Biometrical Journal</i> , 2017, 59, 804-825.	0.6	41
43	A Practical Comparison of Group-Sequential and Adaptive Designs. <i>Journal of Biopharmaceutical Statistics</i> , 2005, 15, 719-738.	0.4	40
44	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 483-497.	0.6	40
45	Estimation following selection of the largest of two normal means. <i>Journal of Statistical Planning and Inference</i> , 2008, 138, 1629-1638.	0.4	37
46	Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. <i>Clinical Oncology</i> , 2013, 25, 109-116.	0.6	37
47	Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. <i>Pharmaceutical Statistics</i> , 2005, 4, 119-128.	0.7	36
48	Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. <i>Statistics in Medicine</i> , 2013, 32, 2893-2910.	0.8	36
49	Stopping rules for phase II studies. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 523-529.	1.1	35
50	Interim analyses and sequential designs in phase III studies. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 394-399.	1.1	34
51	On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. <i>Annals of Oncology</i> , 2019, 30, 506-509.	0.6	34
52	Repeated measures proportional odds logistic regression analysis of ordinal score data in the statistical software package R. <i>Computational Statistics and Data Analysis</i> , 2009, 53, 632-641.	0.7	33
53	Effectiveness and cost-effectiveness of a universal parenting skills programme in deprived communities: multicentre randomised controlled trial. <i>BMJ Open</i> , 2013, 3, e002851.	0.8	33
54	Repeated challenge with prion disease: The risk of infection and impact on incubation period. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10960-10965.	3.3	32

#	ARTICLE	IF	CITATIONS
55	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. <i>Brain Communications</i> , 2021, 3, fcab242.	1.5	32
56	Comparison of the spending function method and the christmas tree correction for group sequential trials. <i>Journal of Biopharmaceutical Statistics</i> , 1996, 6, 361-373.	0.4	31
57	Statistical design and analysis of pharmacogenetic trials. <i>Statistics in Medicine</i> , 2005, 24, 1495-1508.	0.8	31
58	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 44.	1.2	31
59	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 461-477.	0.6	31
60	A multi-stage drop-the-losers design for multi-arm clinical trials. <i>Statistical Methods in Medical Research</i> , 2017, 26, 508-524.	0.7	30
61	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 186.	1.2	30
62	Randomised controlled trial evaluating the effectiveness and cost-effectiveness of "Families for Health"™, a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years. <i>Health Technology Assessment</i> , 2017, 21, 1-180.	1.3	30
63	Directions for new developments on statistical design and analysis of small population group trials. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 78.	1.2	29
64	Dose selection in seamless phase II/III clinical trials based on efficacy and safety. <i>Statistics in Medicine</i> , 2009, 28, 917-936.	0.8	28
65	Optimized adaptive enrichment designs. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2096-2111.	0.7	28
66	Comparison of Bayesian and frequentist group-sequential clinical trial designs. <i>BMC Medical Research Methodology</i> , 2020, 20, 4.	1.4	28
67	RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 687.	0.7	28
68	Evaluating the Quality of Subgroup Analyses in Randomized Controlled Trials of Therapist-Delivered Interventions for Nonspecific Low Back Pain. <i>Spine</i> , 2014, 39, 618-629.	1.0	27
69	Flexible sequential designs for multi-arm clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 3269-3279.	0.8	27
70	Determination of the optimal sample size for a clinical trial accounting for the population size. <i>Biometrical Journal</i> , 2017, 59, 609-625.	0.6	27
71	Investigating interventions to increase uptake of HIV testing and linkage into care or prevention for male partners of pregnant women in antenatal clinics in Blantyre, Malawi: study protocol for a cluster randomised trial. <i>Trials</i> , 2017, 18, 349.	0.7	27
72	Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. <i>BMC Medical Research Methodology</i> , 2019, 19, 99.	1.4	27

#	ARTICLE	IF	CITATIONS
73	Local impact of the English arm of the UK Bowel Cancer Screening Pilot study. <i>British Journal of Surgery</i> , 2008, 95, 1172-1179.	0.1	26
74	A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 170-189.	0.4	26
75	Effect of Using the Same vs Different Order for Second Readings of Screening Mammograms on Rates of Breast Cancer Detection. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1956.	3.8	25
76	Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies. <i>Biometrics</i> , 2003, 59, 402-409.	0.8	24
77	Estimation after subpopulation selection in adaptive seamless trials. <i>Statistics in Medicine</i> , 2015, 34, 2581-2601.	0.8	24
78	Optimizing Trial Designs for Targeted Therapies. <i>PLoS ONE</i> , 2016, 11, e0163726.	1.1	24
79	Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. <i>Statistics in Medicine</i> , 2002, 21, 467-480.	0.8	23
80	Bayesian modelling of multivariate quantitative traits using seemingly unrelated regressions. <i>Genetic Epidemiology</i> , 2005, 28, 313-325.	0.6	23
81	Morbidity from diarrhoea, cough and fever among young children in Nigeria. <i>Annals of Tropical Medicine and Parasitology</i> , 2008, 102, 427-445.	1.6	23
82	Reducing animal numbers in the fixed-dose procedure. <i>Human and Experimental Toxicology</i> , 1995, 14, 315-323.	1.1	22
83	Advanced life support cardiac arrest scenario test evaluation. <i>Resuscitation</i> , 2007, 75, 484-490.	1.3	22
84	The effects of a brief intervention to promote walking on Theory of Planned Behavior constructs: A cluster randomized controlled trial in general practice. <i>Patient Education and Counseling</i> , 2015, 98, 651-659.	1.0	22
85	Learning from previous responses in phase I dose-escalation studies. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 1-7.	1.1	21
86	Health service use in families where children enter public care: a nested case control study using the General Practice Research Database. <i>BMC Health Services Research</i> , 2012, 12, 65.	0.9	21
87	Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R. <i>Biometrical Journal</i> , 2020, 62, 1264-1283.	0.6	21
88	Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study. <i>Medical Decision Making</i> , 2021, 41, 37-50.	1.2	21
89	In "big bang" major incidents do triage tools accurately predict clinical priority?: A systematic review of the literature. <i>Injury</i> , 2011, 42, 460-468.	0.7	20
90	Decision-theoretic designs for small trials and pilot studies: A review. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1022-1038.	0.7	20

#	ARTICLE	IF	CITATIONS
91	Randomised controlled trial and economic evaluation of the "Families for Health"™ programme to reduce obesity in children. Archives of Disease in Childhood, 2017, 102, 416-426.	1.0	20
92	Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics, 1998, 54, 279-94.	0.8	20
93	Physiotherapy rehabilitation for osteoporotic vertebral fracture—a randomised controlled trial and economic evaluation (PROVE trial). Osteoporosis International, 2020, 31, 277-289.	1.3	19
94	Comments on the Draft Guidance on "Adaptive Design Clinical Trials for Drugs and Biologics" of the U.S. Food and Drug Administration. Journal of Biopharmaceutical Statistics, 2010, 20, 1125-1131.	0.4	18
95	The effect of real-time CPR feedback and post event debriefing on patient and processes focused outcomes: A cohort study: trial protocol. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2011, 19, 58.	1.1	18
96	Physiotherapy Rehabilitation for Osteoporotic Vertebral Fracture (PROVE): study protocol for a randomised controlled trial. Trials, 2014, 15, 22.	0.7	18
97	Performance characteristics of five triage tools for major incidents involving traumatic injuries to children. Injury, 2016, 47, 988-992.	0.7	18
98	Data-driven treatment selection for seamless phase II/III trials incorporating early outcome data. Pharmaceutical Statistics, 2014, 13, 238-246.	0.7	17
99	Can We Convert Between Outcome Measures of Disability for Chronic Low Back Pain?. Spine, 2015, 40, 734-739.	1.0	17
100	Exact sequential tests for single samples of discrete responses using spending functions. Statistics in Medicine, 2000, 19, 3051-3064.	0.8	16
101	A hierarchical Bayesian model for predicting the functional consequences of amino-acid polymorphisms. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 191-206.	0.5	16
102	Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics, 2018, 17, 214-230.	0.7	16
103	Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs. Statistics in Medicine, 2006, 25, 3081-3092.	0.8	15
104	Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine, 2009, 28, 1321-1338.	0.8	15
105	An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis, 2012, 56, 1150-1160.	0.7	15
106	Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. British Journal of Cancer, 2014, 110, 1950-1957.	2.9	15
107	A recursive partitioning approach for subgroup identification in individual patient data meta-analysis. Statistics in Medicine, 2018, 37, 1550-1561.	0.8	15
108	Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials. Biometrika, 2018, 105, 495-501.	1.3	15

#	ARTICLE	IF	CITATIONS
109	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. <i>Trials</i> , 2021, 22, 203.	0.7	15
110	Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. <i>Health Technology Assessment</i> , 2019, 23, 1-88.	1.3	15
111	A parametric multistate model for the analysis of carcinogenicity experiments. <i>Lifetime Data Analysis</i> , 1995, 1, 327-346.	0.4	14
112	Simple tests for the external validation of mortality prediction scores. <i>Statistics in Medicine</i> , 2009, 28, 377-388.	0.8	13
113	A cluster randomised controlled trial of the efficacy of a brief walking intervention delivered in primary care: Study protocol. <i>BMC Family Practice</i> , 2011, 12, 56.	2.9	13
114	Planning multi-arm screening studies within the context of a drug development program. <i>Statistics in Medicine</i> , 2013, 32, 3424-3435.	0.8	13
115	Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial. <i>Statistics in Medicine</i> , 2015, 34, 3104-3115.	0.8	13
116	To add or not to add a new treatment arm to a multiarm study: A decision theoretic framework. <i>Statistics in Medicine</i> , 2019, 38, 3305-3321.	0.8	13
117	Exercise or manual physiotherapy compared with a single session of physiotherapy for osteoporotic vertebral fracture: three-arm PROVE RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-318.	1.3	13
118	Evaluating the relationship between moral values and vaccine hesitancy in Great Britain during the COVID-19 pandemic: A cross-sectional survey. <i>Social Science and Medicine</i> , 2022, 308, 115218.	1.8	13
119	Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology. <i>Biometrics</i> , 2001, 57, 1089-1095.	0.8	12
120	Statistical evaluation of the Fixed Concentration Procedure for acute inhalation toxicity assessment. <i>Human and Experimental Toxicology</i> , 2003, 22, 575-585.	1.1	12
121	Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 787-801.	0.4	12
122	A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity. <i>Human and Experimental Toxicology</i> , 2011, 30, 217-238.	1.1	12
123	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. <i>BMC Medical Research Methodology</i> , 2018, 18, 20.	1.4	12
124	An Alternative Approach to the Analysis of Animal Carcinogenicity Studies. <i>Regulatory Toxicology and Pharmacology</i> , 1996, 23, 244-248.	1.3	11
125	Statistical evaluation of the revised fixed-dose procedure. <i>Human and Experimental Toxicology</i> , 2002, 21, 183-196.	1.1	11
126	A study of the efficacy and cost-effectiveness of MRSA screening and monitoring on surgical wards using a new, rapid molecular test (EMMS). <i>BMC Health Services Research</i> , 2007, 7, 160.	0.9	11

#	ARTICLE	IF	CITATIONS
127	Measuring the impact and costs of a universal group based parenting programme: protocol and implementation of a trial. BMC Public Health, 2010, 10, 364.	1.2	11
128	A new sighting study for the fixed concentration procedure to allow for gender differences. Human and Experimental Toxicology, 2011, 30, 239-249.	1.1	11
129	Utilizing Rapid Multiple-Locus Variable-Number Tandem-Repeat Analysis Typing To Aid Control of Hospital-Acquired Clostridium difficile Infection: a Multicenter Study. Journal of Clinical Microbiology, 2012, 50, 3244-3248.	1.8	11
130	A comparison of methods for constructing confidence intervals after phase II/III clinical trials. Biometrical Journal, 2014, 56, 107-128.	0.6	11
131	Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection. Statistics in Medicine, 2020, 39, 2568-2586.	0.8	11
132	Protocol for a randomised controlled trial of Subacromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery (START:REACTS). BMJ Open, 2020, 10, e036829.	0.8	11
133	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.9	11
134	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open, 2022, 12, e064173.	0.8	10
135	A Statistical Evaluation of the Fixed Dose Procedure. ATLA Alternatives To Laboratory Animals, 2004, 32, 13-21.	0.7	9
136	Statistical evaluation of an acute dermal toxicity test using the dermal fixed dose procedure. Human and Experimental Toxicology, 2004, 23, 405-412.	1.1	9
137	Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods. Statistics in Medicine, 2012, 31, 2068-2085.	0.8	9
138	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet Journal of Rare Diseases, 2016, 11, 16.	1.2	9
139	An evaluation of the fixed concentration procedure for assessment of acute inhalation toxicity. Regulatory Toxicology and Pharmacology, 2018, 94, 22-32.	1.3	9
140	An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears. Trials, 2019, 20, 694.	0.7	9
141	Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial. Trials, 2020, 21, 84.	0.7	9
142	Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 1022.	1.2	9
143	Facet joint injections for people with persistent non-specific low back pain (Facet Injection Study): a feasibility study for a randomised controlled trial. Health Technology Assessment, 2017, 21, 1-184.	1.3	9
144	Identifying back pain subgroups: developing and applying approaches using individual patient data collected within clinical trials. Programme Grants for Applied Research, 2016, 4, 1-278.	0.4	9

#	ARTICLE	IF	CITATIONS
145	The fixed-dose procedure and the acute-toxic-class method: a mathematical comparison. <i>Human and Experimental Toxicology</i> , 1995, 14, 974-990.	1.1	8
146	A cluster randomized controlled trial of the effectiveness and cost-effectiveness of Intermediate Care Clinics for Diabetes (ICCD): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 164.	0.7	8
147	Optimal adaptive designs for acute oral toxicity assessment. <i>Journal of Statistical Planning and Inference</i> , 2006, 136, 1781-1799.	0.4	7
148	Evaluation of the effectiveness and cost-effectiveness of Families for Health V2 for the treatment of childhood obesity: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 81.	0.7	7
149	Changing case Order to Optimise patterns of Performance in mammography Screening (CO-OPS): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 17.	0.7	7
150	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 157, 163-177.	2.6	7
151	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. <i>Journal of Neurology</i> , 2018, 265, 1795-1802.	1.8	7
152	Point estimation following two-stage adaptive threshold enrichment clinical trials. <i>Statistics in Medicine</i> , 2018, 37, 3179-3196.	0.8	7
153	Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study. <i>Medical Decision Making</i> , 2021, 41, 476-484.	1.2	7
154	Interim analyses in clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 393-393.	1.1	6
155	Opportunities for Reduction in Acute Toxicity Testing via Improved Design. <i>ATLA Alternatives To Laboratory Animals</i> , 2004, 32, 73-80.	0.7	6
156	Software tools for implementing simulation studies in adaptive seamless designs: introducing R package ASD. <i>Trials</i> , 2011, 12, .	0.7	6
157	Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations. <i>Biometrical Journal</i> , 2017, 59, 344-357.	0.6	6
158	Adaptive enrichment designs with a continuous biomarker. <i>Biometrics</i> , 2023, 79, 9-19.	0.8	6
159	Estimating numbers of infectious units from serial dilution assays. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2006, 55, 15-30.	0.5	5
160	Sequentially testing for a gene-drug interaction in a genomewide analysis. <i>Statistics in Medicine</i> , 2008, 27, 2022-2034.	0.8	5
161	Designing a series of decision-theoretic phase II trials in a small population. <i>Statistics in Medicine</i> , 2012, 31, 4337-4351.	0.8	5
162	Facet-joint injections for people with persistent non-specific low back pain (FIS): study protocol for a randomised controlled feasibility trial. <i>Trials</i> , 2015, 16, 588.	0.7	5

#	ARTICLE	IF	CITATIONS
163	Approximately optimal designs for phase II clinical studies. <i>Journal of Biopharmaceutical Statistics</i> , 1998, 8, 469-487.	0.4	4
164	Modified Weibull multi-state models for the analysis of animal carcinogenicity data. <i>Environmental and Ecological Statistics</i> , 2000, 7, 117-133.	1.9	4
165	Including a time-of-year effect in the analysis of a matched case-control study. <i>Statistics in Medicine</i> , 2004, 23, 3193-3207.	0.8	4
166	A hybrid procedure for detecting global treatment effects in multivariate clinical trials: theory and applications to fMRI studies. <i>Statistics in Medicine</i> , 2012, 31, 253-268.	0.8	4
167	An alternative method to analyse the biomarker strategy design. <i>Statistics in Medicine</i> , 2018, 37, 4636-4651.	0.8	4
168	Identification of subgroup effect with an individual participant data meta-analysis of randomised controlled trials of three different types of therapist-delivered care in low back pain. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 191.	0.8	4
169	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). <i>BMJ Open</i> , 2022, 12, e058050.	0.8	4
170	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, 754-764.	1.5	4
171	Decision theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution. <i>Biometrical Journal</i> , 2018, 60, 232-245.	0.6	3
172	Statistical Methods for Combining Clinical Trial Phases II And III. , 2007, , 401-417.		3
173	Two-stage designs for phase II cancer trials with ordinal responses. <i>Contemporary Clinical Trials</i> , 2008, 29, 896-904.	0.8	2
174	Estimating the magnitude of carcinogenic effects in long-term animal studies. <i>Human and Experimental Toxicology</i> , 1995, 14, 643-653.	1.1	1
175	Improving the Efficiency of Fixed-Dose Procedures for the Assessment of Acute Oral Toxicity. <i>Drug Information Journal</i> , 1997, 31, 369-385.	0.5	1
176	An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information. <i>Trials</i> , 2011, 12, .	0.7	1
177	Adaptive Multivariate Global Testing. <i>Journal of the American Statistical Association</i> , 2014, 109, 613-623.	1.8	1
178	Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations. <i>Pharmacoeconomics</i> , 2022, 40, 109-120.	1.7	1
179	Development of a model to demonstrate the impact of National Institute of Health and Care Excellence cost-effectiveness assessment on health utility for targeted medicines. <i>Health Economics (United Kingdom)</i> , 2021, 31, 417.	0.8	1
180	Phase II Clinical Trials. , 0, , 15-31.		0

#	ARTICLE	IF	CITATIONS
181	Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug development programme. <i>Pharmaceutical Statistics</i> , 2009, 8, 287-300.	0.7	0
182	Patterns of health service use in families where children enter public care: a nested case-control study using the general practice research database. <i>Archives of Disease in Childhood</i> , 2010, 95, A6.1-A6.	1.0	0
183	The effect of the 2010 resuscitation guidelines on CPR quality: An observational study. <i>Resuscitation</i> , 2013, 84, S24.	1.3	0
184	Using the NIHR Research Design Service. <i>Paediatrics and Child Health (United Kingdom)</i> , 2014, 24, 572-573.	0.2	0
185	How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired <i>C. difficile</i> infections?. <i>BMC Infectious Diseases</i> , 2014, 14, 154.	1.3	0
186	Editorial for the <i>Biometrical Journal</i> Special Issue ISCB 2016. <i>Biometrical Journal</i> , 2018, 60, 231-231.	0.6	0
187	Efficiency of Adaptive Designs. , 2010, , 25-1-25-16.		0
188	OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter analysis: Preliminary study.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS665-TPS665.	0.8	0
189	OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter tests.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS656-TPS656.	0.8	0
190	Rejoinder to discussion on "Adaptive enrichment designs with a continuous biomarker". <i>Biometrics</i> , 2023, 79, 36-38.	0.8	0
191	The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0